# 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

> **NCT00090246** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 922 (actual)

## Conditions studied

- Postoperative Nausea and Vomiting

## Interventions

- **DRUG:** MK0869, aprepitant
- **DRUG:** Comparator: ondansetron IV

## Key facts

- **NCT ID:** NCT00090246
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05-13
- **Primary completion:** 2005-04-06
- **Final completion:** 2005-04-20
- **Target enrollment:** 922 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090246, "2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00090246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*